about
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapyStat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end.Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid LeukaemiaSynthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.Intestinal perforation after treatment of Burkitt's lymphoma: case report and review of the literature.CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern.Assessing the intracellular fate of rhodium(ii) complexes.Adoptive immunotherapy for AML with CD123-engager T cells.Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children's Oncology Group report.Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia.Cytogenetically cryptic and FISH-negative PML/RARA rearrangement in acute promyelocytic leukemia detected only by PCR: an exceedingly rare phenomenon.Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistanceComparision of four and six color multiparametric flow cytometry panels to diagnose pediatric leukemiasA STAT3 decoy lures AML out of hidingAdult Low-Hypodiploid Acute B-Lymphoblastic Leukemia WithIKZF3Deletion andTP53MutationPediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis
P50
Q28539096-E83E3005-089E-46BC-AB6E-4D26E5CEC1E0Q33298860-AFDDFB67-7894-4844-852D-381643BB7BA9Q33852603-3A1FEB13-0F92-4094-A518-42EE1859B7CEQ36940199-CA6271E2-44A2-4D40-9963-1AC147383581Q37295115-0564E205-C48C-4D94-9F34-12E3230E1D30Q38082048-2A16630B-4076-444C-8667-E51E0D0EC64FQ38758807-32E4B1C0-0265-483D-B3E3-849070427888Q38786793-11110152-F360-4BE4-98F4-1CEF0B4E542BQ40106805-BC55A972-DF4F-4D61-9710-56B967931945Q41549856-E5F808E1-B28C-458C-AB10-69F87C29F1FDQ45750942-8D9D67A5-5CD1-4895-B1B6-529390AD2EACQ46624842-44C089AF-5BC1-4931-92E2-40EA3234EE93Q53459150-B5772944-D579-490F-A49D-C4182E18F8AEQ54221603-8A2DB0A5-9DC6-4C45-B4A5-7DD4CDE3109DQ60141632-D230C5E3-8ED9-46CD-8DE2-7EEA397CDE74Q60141633-49608A93-BAE8-4BB2-81ED-41415F3D6135Q60141635-2DEF4BF0-A81A-47C1-B02A-47C476156120Q60141636-FE6F9C6F-DABD-45BD-A792-06D924B5E6C0Q91090002-A34B2F24-9F01-462C-A984-9A7024285735
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michele S Redell
@ast
Michele S Redell
@en
Michele S Redell
@es
Michele S Redell
@nl
Michele S Redell
@sl
type
label
Michele S Redell
@ast
Michele S Redell
@en
Michele S Redell
@es
Michele S Redell
@nl
Michele S Redell
@sl
prefLabel
Michele S Redell
@ast
Michele S Redell
@en
Michele S Redell
@es
Michele S Redell
@nl
Michele S Redell
@sl
P106
P31
P496
0000-0002-2515-3703